Matches in Wikidata for { <http://www.wikidata.org/entity/Q102219300> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q102219300 description "2020 ވަނަ އަހަރުގެ ނޮވެމްބަރުމަހުގެ 17ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q102219300 description "artículu científicu espublizáu en payares de 2020" @default.
- Q102219300 description "scientific article published on 17 November 2020" @default.
- Q102219300 description "wetenschappelijk artikel" @default.
- Q102219300 description "наукова стаття, опублікована 17 листопада 2020" @default.
- Q102219300 name "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 name "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 name "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 type Item @default.
- Q102219300 label "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 label "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 label "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 prefLabel "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 prefLabel "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 prefLabel "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 P1433 Q102219300-904449C3-F374-4B53-A9C2-39981F58902E @default.
- Q102219300 P1476 Q102219300-FDDFDAC2-D1BE-497E-ABFF-DFADF94E01F3 @default.
- Q102219300 P2093 Q102219300-1BDA0AA1-1961-45D0-A0BA-4D24D9FCD847 @default.
- Q102219300 P2093 Q102219300-1E8387CB-E77F-49CD-8156-40B9AEF1D86A @default.
- Q102219300 P2093 Q102219300-B4DC2EE3-2F35-4192-A373-D658683D7FC0 @default.
- Q102219300 P2093 Q102219300-BED3933D-25F2-4BA9-9F4D-6A9938A2F55F @default.
- Q102219300 P2093 Q102219300-C3524C96-99F0-477E-8EA5-95044AA36210 @default.
- Q102219300 P2093 Q102219300-E23D7129-D9A4-4DD2-A60A-7B68699CEED3 @default.
- Q102219300 P2093 Q102219300-EC0E0CC9-7629-451F-83CE-7D7AEAF4A794 @default.
- Q102219300 P31 Q102219300-366FC4D3-F167-4DEF-B0B9-15D4F0981DB9 @default.
- Q102219300 P356 Q102219300-F4253157-4270-44AA-85E1-0B857F685928 @default.
- Q102219300 P577 Q102219300-99A485C4-0163-4CD2-A6E3-AE5945CEC160 @default.
- Q102219300 P698 Q102219300-166F4E56-C1A2-406C-9D70-AB9DE0818ADF @default.
- Q102219300 P921 Q102219300-66A0B38B-B4B8-47D6-9EDB-A64BCBB3C1BB @default.
- Q102219300 P921 Q102219300-FF1E3072-FFBC-4F45-AAE8-5C2BE50B0BCF @default.
- Q102219300 P356 J.CLINTHERA.2020.10.007 @default.
- Q102219300 P698 33218740 @default.
- Q102219300 P1433 Q15716601 @default.
- Q102219300 P1476 "Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study" @default.
- Q102219300 P2093 "Ales Linhart" @default.
- Q102219300 P2093 "Andrey Gurevich" @default.
- Q102219300 P2093 "Derralynn Hughes" @default.
- Q102219300 P2093 "Fabry Outcome Survey Study Group" @default.
- Q102219300 P2093 "Sandro Feriozzi" @default.
- Q102219300 P2093 "Uma Ramaswami" @default.
- Q102219300 P2093 "Vasiliki Kalampoki" @default.
- Q102219300 P31 Q13442814 @default.
- Q102219300 P356 "10.1016/J.CLINTHERA.2020.10.007" @default.
- Q102219300 P577 "2020-11-17T00:00:00Z" @default.
- Q102219300 P698 "33218740" @default.
- Q102219300 P921 Q1628627 @default.
- Q102219300 P921 Q615645 @default.